



CHINA HEALTH GROUP INC.

中國醫療集團有限公司

(Carrying on business in Hong Kong as “萬全醫療集團”)

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 08225)

THIRD QUARTERLY REPORT 2022

FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2022

THIRD QUARTERLY REPORT 2022
FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2022

CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”)

GEM has been positioned as a market designed to accommodate small and mid-size companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risk of investing in such companies and should make the decision to invest only after due and careful consideration.

Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.

The Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report .

This report, for which the directors (the “Directors”) of China Health Group Inc. (the “Company”) collectively and individually accept responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of the Stock Exchange (the “GEM Listing Rules”) for the purpose of giving information with regard to the Company and its subsidiaries (together, the “Group”). The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this report is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this report misleading



CHINA HEALTH GROUP INC.

中國醫療集團有限公司

(Carrying on business in Hong Kong as “萬全醫療集團”)

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 08225)

FINANCIAL HIGHLIGHTS

1. The Group achieved a turnover of RMB33,316,000 for the nine months ended 30 September 2022 (the “Period”), representing an decrease of approximately 40.3% compared with the corresponding period of 2021.
2. The Group achieved profit before taxation of about RMB19,259,000 for the Period, representing a decrease of approximately 38.0% as compared with the corresponding period of 2021.
3. Basic earnings per share are approximately RMB1.64 cents for the Period, representing a decrease of approximately 36.5% as compared with the corresponding period of 2021.
4. The Board does not recommend the payment of any interim dividends for the nine months ended 30 September 2022.

THIRD QUARTERLY RESULTS (UNAUDITED)

The board of Directors (the “Board”) is here to present the condensed unaudited consolidated third quarterly results of the Group for the nine months ended 30 September 2022, together with the comparative condensed unaudited consolidated figures for the corresponding period in 2021: